Latest Ab Science Paris (ABSCF) Headlines AB
Post# of 5
Posted On: 03/08/2014 4:34:50 PM
Latest Ab Science Paris (ABSCF) Headlines
AB Science: initiation of a new phase 3 study with masitinib in Prostate Cancer, following encouraging survival results obtained in a phase 2 study
GlobeNewswire - Thu Feb 20, 11:09AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with docetaxel in first line treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC).
AB Science announces initiation of a new phase 3 study in oncology with masitinib in patients with metastatic colorectal cancer
GlobeNewswire - Mon Dec 02, 11:32AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with FOLFIRI in patients with metastatic colorectal cancer (mCRC) in first relapse.
AB Science: Masitinib successfully passes futility analysis in pivotal clinical study in Mastocytosis
GlobeNewswire - Mon Nov 11, 11:03AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the independent Data and Safety Monitoring Board (DSMB) created as part of the company pivotal clinical study evaluating masitinib in the treatment of mastocytosis has recommended continuation of the study, based upon completion of the futility analysis included in the study protocol.
Acceleration of Clinical Program in Amyotrophic Lateral Sclerosis (ALS) Confirms the Proof of Efficacy Data Obtained in Animals
GlobeNewswire - Wed Nov 06, 12:26PM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.
AB Science : Financial Results and Key Events of First Half-Year 2013
Marketwire - Fri Aug 30, 12:58PM CDT
AB Science SA (EURONEXT PARIS: AB) (ISIN: FR0010557264)
AB Science and consortium partners receive EUR8.6m from Epifrance as part of programme for the development of a new therapy in Alzheimer's disease
M2 - Tue Jul 23, 5:03PM CDT
AB Science SA (Paris:AB), a pharmaceutical company specialised in protein kinase inhibitors (PKIs), announced today a new partnership in the development of a new targeted therapy in Alzheimer's disease.
AB Science and Its Partners Receive EUR 8.6 Million as Part of a Project Supported by Bpifrance in Alzheimer's Disease
Marketwire - Tue Jul 23, 2:40AM CDT
AB Science SA (EURONEXT PARIS: AB) (ISIN: FR0010557264), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the creation of a partnership in the development of a new targeted therapy in Alzheimer's disease.
AB Science Issues 2 Convertible Bonds for a Total Amount of 12.5 M EUR
Marketwire - Mon Jun 10, 1:04PM CDT
AB Science Issues 2 Convertible Bonds for a Total Amount of 12.5 M EUR Bearing an Average Annual Interest Rate of 0.18% at the Reference Price for Conversion of 24.38 EUR or 29.30 EUR per Share
AB Science: 2012 Annual Financial Results and 2013 First Quarter Revenue
Marketwire - Mon Apr 29, 1:17PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), reports today its annual financials as of 31 December 2012, as well as its revenue for the first quarter of 2013, and provides an update on its activities. The Board who met on April 24th, 2013, reviewed and approved the consolidated financial statement for the year closing on 31 December 2012. Audit procedures on consolidated financial statements were performed. The audited financial report is available on the Company's website.
AB Science: initiation of a new phase 3 study with masitinib in Prostate Cancer, following encouraging survival results obtained in a phase 2 study
GlobeNewswire - Thu Feb 20, 11:09AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with docetaxel in first line treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC).
AB Science announces initiation of a new phase 3 study in oncology with masitinib in patients with metastatic colorectal cancer
GlobeNewswire - Mon Dec 02, 11:32AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with FOLFIRI in patients with metastatic colorectal cancer (mCRC) in first relapse.
AB Science: Masitinib successfully passes futility analysis in pivotal clinical study in Mastocytosis
GlobeNewswire - Mon Nov 11, 11:03AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the independent Data and Safety Monitoring Board (DSMB) created as part of the company pivotal clinical study evaluating masitinib in the treatment of mastocytosis has recommended continuation of the study, based upon completion of the futility analysis included in the study protocol.
Acceleration of Clinical Program in Amyotrophic Lateral Sclerosis (ALS) Confirms the Proof of Efficacy Data Obtained in Animals
GlobeNewswire - Wed Nov 06, 12:26PM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.
AB Science : Financial Results and Key Events of First Half-Year 2013
Marketwire - Fri Aug 30, 12:58PM CDT
AB Science SA (EURONEXT PARIS: AB) (ISIN: FR0010557264)
AB Science and consortium partners receive EUR8.6m from Epifrance as part of programme for the development of a new therapy in Alzheimer's disease
M2 - Tue Jul 23, 5:03PM CDT
AB Science SA (Paris:AB), a pharmaceutical company specialised in protein kinase inhibitors (PKIs), announced today a new partnership in the development of a new targeted therapy in Alzheimer's disease.
AB Science and Its Partners Receive EUR 8.6 Million as Part of a Project Supported by Bpifrance in Alzheimer's Disease
Marketwire - Tue Jul 23, 2:40AM CDT
AB Science SA (EURONEXT PARIS: AB) (ISIN: FR0010557264), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the creation of a partnership in the development of a new targeted therapy in Alzheimer's disease.
AB Science Issues 2 Convertible Bonds for a Total Amount of 12.5 M EUR
Marketwire - Mon Jun 10, 1:04PM CDT
AB Science Issues 2 Convertible Bonds for a Total Amount of 12.5 M EUR Bearing an Average Annual Interest Rate of 0.18% at the Reference Price for Conversion of 24.38 EUR or 29.30 EUR per Share
AB Science: 2012 Annual Financial Results and 2013 First Quarter Revenue
Marketwire - Mon Apr 29, 1:17PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), reports today its annual financials as of 31 December 2012, as well as its revenue for the first quarter of 2013, and provides an update on its activities. The Board who met on April 24th, 2013, reviewed and approved the consolidated financial statement for the year closing on 31 December 2012. Audit procedures on consolidated financial statements were performed. The audited financial report is available on the Company's website.
(0)
(0)AB Science, Paris (ABSCF) Stock Research Links
Scroll down for more posts ▼